Treatment option for dry eye secondary to graft-vs-host disease
March 25, 2021
Product offers improvement in objective dry eye disease measures, providing relief.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Dry Eye
Bausch + Lomb announces topline results for phase III trial of NOV03 to treat DED associated with MGD
April 13, 2021
Bausch + Lomb and Novaliq GmbH have announced statistically significant topline data from the first phase 3 trial analyzing the investigational drug NOV03 as a first-in-class eye drop to treat dry eye disease associated with MGD.
Minocycline shows promise in dry eye trial
March 19, 2021
Phase 2 trial of 0.3% minocycline microparticle suspension shows promise in dry eye diseases associated with Inflamed meibomian gland dysfunction
Mask up ... and dry out?
March 18, 2021
Cynthia Matossian, MD, FACS, ABES, explores the tie between mask wear and dry eye, causes behind a growing number of MGD cases, and offers mask safety tips for patient treatment.
Results of dry eye trial released
March 18, 2021
RegeneRx Biopharmaceuticals announces that its ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops did not meet its primary outcome measures.
Managing pandemic-driven dry eye with nutrition
March 07, 2021
Peter J. Polack, MD, FACS, of Ocala Eye, discusses how proper patient education and nutrition have been key to managing an increase in dry eye patients during the pandemic.
Oyster Point Pharma receives FDA filing acceptance of NDA for OC-01 nasal spray to treat DED
March 02, 2021
The FDA has accepted Oyster Point Pharma's New Drug Application (NDA) for its OC-01 (varenicline) nasal spray to treat dry eye disease.
Investigators zoom in on future of dry eye treatment
March 02, 2021
Autologous serum eye drops and blood products offer hope to patients.
The sky is the limit for allergy pipeline
February 18, 2021
Growing patient pool is driving clinical trial investment.
Study: Sore eyes a common symptom in COVID-19 patients
January 25, 2021
Ocular symptoms in COVID-19 patients may be more common than previously thought — with sore eyes a significant sign of disease.